Scarica l'app Stockscreener
11.85
16.86%
1.71
Pre-mercato:
11.91
0.06
+0.51%
Replimune Group Inc Borsa (REPL) Ultime notizie
Barclays maintains Replimune stock with $17 target By Investing.com - Investing.com UK
Replimune stock soars on FDA priority review for melanoma treatment - MSN
Replimune stock price target raised to $27 by BMO Capital - Investing.com South Africa
Replimune Stock Soars 16% on FDA Priority Review for Advanced Me - GuruFocus.com
Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy - Yahoo Finance
Replimune stock soars on FDA priority review for melanoma treatment By Investing.com - Investing.com Australia
Replimune Group (NASDAQ:REPL) Shares Gap UpTime to Buy? - MarketBeat
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday - Benzinga
FDA accepts Replimune's advanced melanoma therapy BLA - Investing.com
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma - The Manila Times
FDA Grants Priority Review to Replimune's Melanoma Treatment RP1, Breakthrough Therapy Status Secured - StockTitan
JPMorgan Chase & Co. Raises Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Trend Tracker for (REPL) - Stock Traders Daily
Replimune's SWOT analysis: biotech firm's stock poised for growth in oncology - MSN
Replimune Group (NASDAQ:REPL) Trading Down 6.6%Here's Why - MarketBeat
Barclays PLC Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Barclays PLC Has $1.74 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Replimune Awards Equity Incentives to 30 New Hires, Including 253,820 Shares in Options and RSUs - StockTitan
Replimune Group Inc (REPL-Q) QuotePress Release - The Globe and Mail
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials - The Manila Times
Replimune Launches Two Major Clinical Trials for Melanoma and Liver Cancer Treatment RP2 - StockTitan
Replimune Group, Inc. (NASDAQ:REPL) Receives $17.29 Consensus PT from Brokerages - Defense World
Replimune Group (NASDAQ:REPL) Stock Price Up 9.5%What's Next? - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Increases Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Geode Capital Management LLC Acquires 217,308 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Replimune's stock surges 19% after-hours on FDA BLA submission - MSN
Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Barclays PLC - Defense World
Replimune Group to Present at J.P. Morgan Healthcare Conference: Key Biotech Updates Coming - StockTitan
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
State Street Corp Buys 1,182,181 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Jane Street Group LLC Sells 274,078 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Trading 8.2% HigherTime to Buy? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 6,759 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Insider Selling: Replimune Group, Inc. (NASDAQ:REPL) CEO Sells 10,000 Shares of Stock - MarketBeat
Replimune CEO Sushil Patel sells $124,200 in company stock - Investing.com
Replimune CEO Sushil Patel sells $124,200 in company stock By Investing.com - Investing.com Australia
Wellington Management Group LLP Decreases Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
BNP Paribas Financial Markets Buys 6,748 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Trading Down 4.7%Here's Why - MarketBeat
Replimune management to meet with Jefferies - Nasdaq
When (REPL) Moves Investors should Listen - Stock Traders Daily
Replimune's SWOT analysis: biotech's melanoma treatment stock nears key milestones By Investing.com - Investing.com South Africa
Replimune's SWOT analysis: biotech's melanoma treatment stock nears key milestones - Investing.com India
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):